We use cookies to run this site. Analytics cookies help us understand how you use it and are off until you say yes. You can change your mind at any time from the privacy preferences icon at the bottom right.We use cookies to run this site and to understand how it's used. You can opt out at any time from the privacy preferences icon at the bottom right. Cookie policy
The Journal of Clinical Oncology Podcast presents analyses and discussions centered on the latest findings published in ASCO's flagship Journal of Clinical Oncology. Host Dr. Davide Soldato facilitates interviews and scholarly discourse on the most impactful published findings. The Journal of…
What long-term outcomes can be achieved with neoadjuvant cemiplimab, and how does immunotherapy reshape the treatment landscape for advanced cutaneous squamous cell carcinoma? Host Dr. Davide Soldato interviews Dr. Neil Gross on his simultaneous publication presented at ESMO 2026 "A Phase 2 Study of Neoadjuvant…
What pCR rates can be achieved with neoadjuvant THP, and which patients are most likely to respond? Host Dr. Davide Soldato interviews Dr. Nadine Tung on her article, "Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2-Positive Breast Cancer: Secondary…
Host Dr. Jake New interviews Dr. Makoto Tahara about the JCO article "Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer." They discuss clinical considerations for individualizing treatment…
How does dexrazoxane affect left ventricular function over time after doxorubicin treatment for childhood cancer? Host Dr. Davide Soldato sits down with Dr. Erin Mobley and Dr. Eric Chow to discuss their article, "Longitudinal Change in Cardiac Function After Doxorubicin and Dexrazoxane: A Report from COG ALTE11C2."…
Guest Dr. Vedang Murthy and host Davide Soldato discuss JCO article, "Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer" and delve into trial design, results, clinical implications, and future…
In this episode of JCO Article Insights, host Ash Gurumurthi summarizes the article "Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma," by Mehta-Shah and colleagues. LINK TO FULL TRANSCRIPT
Guests Dr. Elise Park, Dr. Jamie Ostrov and host Dr. Davide Soldato discuss JCO article "Virtual Sustained Tobacco Treatment for Cancer Patients: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) within the NCI Community Oncology Research Program (NCORP)" and their groundbreaking trial on virtual tobacco cessation…
Guests Akash Kulgod and Dr. Sanjeev Kulgod and host Dr. Davide Soldato discuss JCO article, "Canine Olfaction Combined with Bayesian Modeling for Multi Cancer Detection from Breath Samples, a Phase 2 Study in India" and the innovative breath-based canine olfaction for multi-cancer detection in low-resource settings…
JCO Editorial Fellow Dr. Ash Gurumurthi and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2026 Simultaneous Publication paper "Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study." LINK TO FULL TRANSCRIPT
JCO Podcast host Dr. Davide Soldato and JCO Associate Editor Dr. Dr. Eileen M. O'Reilly discuss the ASCO 2026 Simultaneous Publication paper "Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial." LINK TO FULL…
JCO Editorial Fellow Dr. Yuvanesh Vedaraju and JCO Associate Editor Dr. Kathy Miller discuss the ASCO 2026 Simultaneous Publication paper "Low-Dose Tamoxifen in Non-Invasive Breast Neoplasia: Long-Term Results from an Individual Participant Data Pooled Analysis." LINK TO FULL TRANSCRIPT
JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Umang Swami discuss the ASCO 2026 Simultaneous Publication paper "Neoadjuvant Sacituzumab Govitecan in Patients with Muscle-Invasive Bladder Cancer: Primary Results of SURE-01 Trial." LINK TO FULL TRANSCRIPT
JCO Editorial Fellow Dr. Jake New and JCO Associate Editor Dr. Andrea Necchi discuss the ASCO 2026 Simultaneous Publication paper "Addition of Intravesical Recombinant BCG to Perioperative Chemo-Immunotherapy in Muscle-Invasive Bladder Cancer: Primary Analysis of the Single Arm Phase 2 Trial SAKK 06/19." LINK TO FULL…
Guest Dr. Glenwood Goss and host Dr. Davide Soldato discuss JCO article, "Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer" and the implications of minimal residual disease, results regarding the efficacy of immunotherapy in the adjuvant setting, and the evolving strategies for patient…
Host Jake New summarizes and offers insights into the JCO article by Licitra et al., "Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study." LINK TO FULL TRANSCRIPT
Guest Dr. John Wingard and host Dr. Davide Soldato discuss JCO article, "Randomized Non-inferiority Trial of a Liberalized Diet Versus the Neutropenic Diet in Hematopoietic Stem Cell Transplant and Acute Leukemia Patients," the reason behind the trial, its design, methodology, results, and the implications for future…
In this episode of JCO Article Insights, host Dr. Ash Gurumurthi summarizes JCO articles, "Phased Variant–Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study" and " Prospective Validation of Circulating Tumor DNA Measurable…
Guest Dr. John Gore and host Dr. Davide Soldato discuss JCO article, "12-Month Results from the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent Non-Muscle Invasive Bladder Cancer," which compares radical cystectomy and bladder sparing therapy for patients with recurrent high-grade…
In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, "Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial," by Harter et al. TRANSCRIPT Melis Canturk: Hello, and…
In this episode of JCO Article Insights, host Dr. Melis Canturk summarizes the article, "Phase 2 Trial of Ribociclib plus Letrozole in Women with Recurrent Low-Grade Serous Cancer of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial," by Slomovitz et al. TRANSCRIPT Melis Canturk: Hello, and welcome to JCO…
Host Dr. Davide Soldato and guests Dr. David Einstein and Dr. Ravi Madan discuss JCO article, "National Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations," underscoring the need for a consensus on clinical trial designs implementing novel endpoints in…
Host Dr. Davide Soldato and guests Dr. Kerin Adelson and Dr. Maureen Canavan discuss JCO article "Association Between Systemic Anticancer Therapy Administration Near the End of Life with Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality," highlighting adverse…
Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to…
JCO Editor-in-Chief Dr. Jonathan Friedberg is joined by colleagues Dr. Jennifer Woyach, Dr. Wojciech Jurczak, and Dr. Matthew Davids to discuss simultaneous publications presented at ASH 2025 on pertibrutinib, a new upfront treatment option for patients with chronic lymphocytic leukemia. TRANSCRIPT The disclosures for…
Apple Podcasts
Spotify
Website